A PEDV infection plasmid, a PEDV mutant virus, its construction method and application

By constructing a PEDV infection plasmid using Red recombination technology and mutating lysine at position 61 of the ORF3 protein to arginine, the problem of increasing viral titer in existing vaccines was solved, resulting in a significant increase in viral titer, enhanced immune response, reduced production costs, and improved vaccine efficacy.

CN122302010APending Publication Date: 2026-06-30YANGZHOU UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
YANGZHOU UNIV
Filing Date
2026-04-03
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing inactivated vaccines are prone to damage to viral antigens during the preparation process, resulting in decreased immunogenicity and inability to replicate in the body. They require adjuvants and multiple high-dose immunizations to provide effective protection. Furthermore, the prevalence of highly pathogenic PEDV strains makes vaccine control a serious challenge, and increasing viral titers is difficult.

Method used

PEDV infection plasmids were constructed using Red recombination technology. The 61st lysine of the ORF3 protein was mutated to arginine to enhance viral replication. A PEDV mutant virus was constructed and recombinant viruses were rescued, thereby increasing viral titer.

Benefits of technology

It significantly increased the PEDV viral titer, providing a new approach for efficient vaccine production, enhancing the immune response, reducing production costs, and improving the feasibility and control capabilities of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122302010A_ABST
    Figure CN122302010A_ABST
Patent Text Reader

Abstract

This invention discloses a PEDV infectious plasmid, a PEDV mutant virus, its construction method, and its applications. This invention also provides a method for increasing PEDV viral titer. This invention identifies for the first time that lysine 61 (K61) of ORF3 is a key site for ubiquitination degradation, and then uses Red recombination technology to construct an infectious PEDV clone with a single-point mutation of ORF3-K61R. Experimental results show that the viral titer of the recombinant virus rPEDV-ORF3-K61R is significantly increased. This invention provides a new approach to improving viral titer through targeted modification of PEDV vaccine strains, and plays an important supporting role in promoting PEDV vaccine development.
Need to check novelty before this filing date? Find Prior Art